Guillaume Cartron has been newly elected as CALYM Steering Committee President.

In June 2020, Guillaume CARTRON is elected President of the Steering Committee of the CALYM CALYM Carnot Institute brings together teams of academic, translational and clinical research able to conduct the full development of medical therapies or diagnostic tools for lymphoma, currently the 1st blood cancer and 6th global most common cancer worldwide. In front of this major public health problem, the 20 CALYM entities , including the cooperative group, LYSA (Lymphoma Study Association), its clinical research operation structure, LYSARC (Lymphoma Academic Research Organisation) and 18 public research laboratories, offer a unique R&D approach, from basic research to the evolution of standards of care.

Guillaume CARTRON was trained at the François Rabelais University in Tours, France. He is a doctor of medicine and doctor of life sciences. He successively held a position as a hospital practitioner at the CHU de Tours, a medical specialist at the Victor Hugo Clinic, Le Mans, then a position as University Professor at the University of Montpellier where he has been practicing since 2006.

He was involved very early in the field of immunotherapy and particularly in understanding the mechanisms of action of monoclonal antibodies for therapeutic use. He is the author of numerous articles in this field as well as in onco-hematology, member of the UMR-CNRS 5535 and responsible for the “resistance to treatments” axis of the SIRIC Montpellier Cancer. He is the director of the EVOCAN “University Heteroclonality and Personalized Treatments” University Hospital Federation, which brings together 300 researchers from the University of Montpellier involved in cancer research. He has been a member of the Labex MabImprove and the CALYM Lymphoma Carnot Institute since their creation. He is a member of the scientific council, the office and the board of directors of LYSA, of which he chairs the follicular lymphoma commission.

Since 2012 he has headed the Department of Clinical Hematology at the Montpellier University Hospital. This 57-bed department performs 80 allogeneic transplants, 110 autologous transplants, 13,500 consultations and 8,700 day hospital stays annually. In 2019, 30 patients received treatment with CAR T-cells. This department is particularly involved in clinical research (phase I to III) with 70 clinical trials and more than 400 patients included in 2019 in a clinical trial. The Clinical Hematology department is labeled CLIP2 by the INCA for early phase trials and to date has a prospective epidemiological, clinical and biological cohort / collection of more than 2,000 patients with malignant hemopathies including 800 patients with lymphoma.